Page 2478 - Williams Hematology ( PDFDrive )

2449
2448 Index Index 2449

Idelalisib, 1538 IGHV (immunoglobulin heavy-chain mechanism of action, 338
for chronic lymphocytic leukemia, 1529, variable) region, 1531, 1531t, pharmacology, 338, 339t, 340–341
1540 1532t, 1542 during pregnancy, 1459
for mantle cell lymphoma, 1659 IGJH, 1164f for primary myelofibrosis, 1329
Id family, 270 IGKV, 1165f, 1166 resistance to, 178, 318, 319t, 340–341,
IDH (isocitrate dehydrogenase), 170, 198, IGLC, 1165f 1279, 1456–1457, 1457t
199f, 337, 337f IH7R, 232t structure, 340f
IDH1/2 IHH (Indian hedgehog), 54 Imerslund-Gräsbeck disease, 607
in acute myelogenous leukemia, 226t, Ii (I/i) antigens, 835, 2333t, 2334t, 2337, 2340 Imiglucerase, for Gaucher disease, 1127
1376, 1378t, 1379 I-κB, 209 Imipenem, 384, 387t
in myelodysplastic syndromes, 228t, 1346t, I-κB-kinase (IKK), 251, 252, 298 Imiquimod, 1686
1351 Ikaros Imitation SWI- (ISWI-) remodelers, 166,
in Ph-chromosome negative in gene activation, 167 166f
myeloproliferative neoplasms, 229t in hematopoietic stem cell to common Immune antibodies, 2347–2348
IDH (isocitrate dehydrogenase) inhibitors, lymphoid progenitor commitment, Immune cell therapy (adoptive cellular
337f 262 therapy)
Idiopathic CD4+ T lymphocytopenia, 1206 in lymphopoiesis, 1155 future directions, 416
Idiopathic neutropenia, 995 IKBKG, 1215, 1220 of malignancy, 412–416, 412t
Idiopathic pneumonia syndrome (IPS), 368 IKKγ (inhibitor of κB kinase γ), 298 genetic retargeting of T cells for,
Idiopathic thrombocytopenic purpura. See IKZF1 414–416, 414f
Immune thrombocytopenia (ITP) in acute lymphoblastic leukemia, 183, leukemia, 413–414
IFN. See under Interferon (IFN) 1507, 1508 melanoma, 412–413
IFNG, 1573 in B-cell acute lymphoblastic leukemia, of viral diseases, 409–412
Ifosfamide. See also CODOX-M/IVAC 232t cytomegalovirus infection, 409–411,
regimen detection, 177f 410f, 411f
for acute lymphoblastic leukemia, 1515 in Philadelphia chromosome-like B-cell Epstein-Barr virus infection, 411–412
for α-heavy-chain disease, 1808 acute lymphoblastic leukemia, 233t multispecific T-cell therapy, 412
for Burkitt lymphoma, 1675, 1675t, 1676 in Ph-negative myeloproliferative Immune complex mechanism, 830
for diffuse large B-cell lymphoma, 1628 neoplasms, 229t Immune dysregulation, polyendocrinopathy,
for enteropathy-associated T-cell IL. See under Interleukin (IL) enteropathy, X-linked–like
lymphoma, 1700 IL2RB, 232t syndromes, 1223–1224
high-dose, 331t, 332t IL2RG, 453, 1217 Immune dysregulation, polyendocrinopathy,
for Hodgkin lymphoma, 1616 IL4, 1573 enteropathy, X-linked syndrome
for malignant histiocytic diseases, 1110 IL7R, 1217 (IPEX syndrome), 1181, 1215t,
mechanism of action, 329 Illumina sequencing-by-synthesis method, 1223
pharmacology, 330 156–157, 156f Immune function. See also Adaptive
Ig. See under Immunoglobulin (Ig) Imatinib immunity; Innate immunity
IGF-1 (insulin-like growth factor-1), 487 for acute lymphoblastic leukemia, 1518 aging and, 135–136, 136f
IGH. See Immunoglobulin heavy-chain for acute myelogenous leukemia, 1403 basophilia and, 971
(IGH) genes adverse effects, 339t, 341, 1451t, 1453 eosinophils and, 952
IGH in children and older patients, 1452–1453 iron deficiency and, 631–632
in Burkitt lymphoma, 1598 for chronic eosinophilic leukemia, 1470 splenic, 91
in chronic lymphocytic leukemia, 187, for chronic myelogenous leukemia. See T-cell disorders and impaired, 1195–1197
1592 Chronic myelogenous (myeloid) Immune neutropenia, 995
in myeloma, 188, 1735 leukemia (CML), therapy Immune reconstitution inflammatory
IGHD, 1164f for chronic myelomonocytic leukemia, syndrome (IRIS), 1242
IGHV 1469 Immune-related fibrosis, 1330
in chronic lymphocytic leukemia, 231t comparison with other tyrosine kinase Immune senescence, 136
in extranodal marginal zone lymphoma, inhibitors, 1451t Immune thrombocytopenia (ITP),
1664, 1664t drug interactions, 339t, 1451t 1999–2009
gene complex, 1164f gene mutations and response to, 1279, primary
in mantle cell lymphoma, 236t 1452 bleeding risk in, 2001–2002, 2002t
in nodal marginal zone lymphoma, 1667 after hematopoietic cell transplantation, in children, 2001, 2002t
in splenic marginal zone lymphoma, 1461–1462 classification, 2001
1666 for hypereosinophilic syndrome, 959 clinical features, 2001–2002, 2002t, 2107
IGHV4–34, 828 for mastocytosis, 977 differential diagnosis, 2003

Kaushansky_index_p2393-2506.indd 2449 9/21/15 3:22 PM